BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31688604)

  • 1. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors.
    Shen C; Gu D; Zhou S; Xu Y; Sarshekeh AM; Halperin D; Shih YT; Yao JC; Dasari A
    Pancreas; 2019; 48(10):1373-1379. PubMed ID: 31688604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study.
    Zhou H; Zhang Y; Wei X; Yang K; Tan W; Qiu Z; Li S; Chen Q; Song Y; Gao S
    Cancer Med; 2017 Nov; 6(11):2745-2756. PubMed ID: 28980417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
    Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
    JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study.
    Gosain R; Ball S; Rana N; Groman A; Gage-Bouchard E; Dasari A; Mukherjee S
    Cancer; 2020 Feb; 126(4):792-799. PubMed ID: 31714595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine tumor epidemiology: contrasting Norway and North America.
    Hauso O; Gustafsson BI; Kidd M; Waldum HL; Drozdov I; Chan AK; Modlin IM
    Cancer; 2008 Nov; 113(10):2655-64. PubMed ID: 18853416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
    JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database.
    Punekar SR; Kaakour D; Masri-Lavine L; Hajdu C; Newman E; Becker DJ
    Am J Clin Oncol; 2020 Dec; 43(12):846-849. PubMed ID: 32910023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial disparities in colorectal cancer survival: to what extent are racial disparities explained by differences in treatment, tumor characteristics, or hospital characteristics?
    White A; Vernon SW; Franzini L; Du XL
    Cancer; 2010 Oct; 116(19):4622-31. PubMed ID: 20626015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant neuroendocrine tumors: incidence and outcomes in pediatric patients.
    Allan B; Davis J; Perez E; Lew J; Sola J
    Eur J Pediatr Surg; 2013 Oct; 23(5):394-9. PubMed ID: 23444065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial Differences in Gastroenteropancreatic Neuroendocrine Tumor Treatment and Survival in the United States.
    Kessel E; Naparst M; Alpert N; Diaz K; Ahn E; Wolin E; Taioli E; Kim MK
    Pancreas; 2021 Jan; 50(1):29-36. PubMed ID: 33370020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics associated with differences in survival among black and white women with breast cancer.
    Silber JH; Rosenbaum PR; Clark AS; Giantonio BJ; Ross RN; Teng Y; Wang M; Niknam BA; Ludwig JM; Wang W; Even-Shoshan O; Fox KR
    JAMA; 2013 Jul; 310(4):389-97. PubMed ID: 23917289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging and widening colorectal carcinoma disparities between Blacks and Whites in the United States (1975-2002).
    Irby K; Anderson WF; Henson DE; Devesa SS
    Cancer Epidemiol Biomarkers Prev; 2006 Apr; 15(4):792-7. PubMed ID: 16614125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparities in Breast Cancer Survival by Socioeconomic Status Despite Medicare and Medicaid Insurance.
    Silber JH; Rosenbaum PR; Ross RN; Reiter JG; Niknam BA; Hill AS; Bongiorno DM; Shah SA; Hochman LL; Even-Shoshan O; Fox KR
    Milbank Q; 2018 Dec; 96(4):706-754. PubMed ID: 30537364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial Disparities and Trends in Pancreatic Cancer Incidence and Mortality in the United States.
    Tavakkoli A; Singal AG; Waljee AK; Elmunzer BJ; Pruitt SL; McKey T; Rubenstein JH; Scheiman JM; Murphy CC
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):171-178.e10. PubMed ID: 31202981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epidemiology of gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Chan A; Svejda B; Kidd M; Modlin IM
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):1-18, vii. PubMed ID: 21349409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial differences in the treatment of early-stage lung cancer.
    Bach PB; Cramer LD; Warren JL; Begg CB
    N Engl J Med; 1999 Oct; 341(16):1198-205. PubMed ID: 10519898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and survival patterns of rare anal canal neoplasms using the surveillance epidemiology and end results registry.
    Metildi C; McLemore EC; Tran T; Chang D; Cosman B; Ramamoorthy SL; Saltzstein SL; Sadler GR
    Am Surg; 2013 Oct; 79(10):1068-74. PubMed ID: 24160801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database.
    Cao LL; Lu J; Lin JX; Zheng CH; Li P; Xie JW; Wang JB; Chen QY; Lin M; Tu RH; Huang CM
    Eur J Surg Oncol; 2018 Oct; 44(10):1628-1633. PubMed ID: 29983275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics and Prognostic Factors of Early-Onset Pancreatic Neuroendocrine Tumors.
    Shi M; Zhou B
    Cancer Control; 2021; 28():1073274820986827. PubMed ID: 33491476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus.
    Sherman ME; Devesa SS
    Cancer; 2003 Jul; 98(1):176-86. PubMed ID: 12833470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.